Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.
Introduction
Conventional cytotoxic anticancer drugs have rarely been reported to induce hypopituitarism in adult-onset cancer patients (1) . Although recent advances, especially those targeting disease-specific molecular elements, have improved the prognosis of several malignancies, new side effects, including hypopituitarism, have emerged (1) .
Nivolumab, an anti-programmed death-1 (PD1) antibody, is widely used for the treatment of several malignancies (2) , such as malignant melanoma (3), non-small-cell lung cancer (4) and renal cell cancer (5) . However, although it is clinically effective, it frequently causes immune-related adverse events (irAEs) including vitiligo, colitis, hepatitis, pneumonitis and endocrinopathies. Nivolumab-induced thyroiditis but not hypophysitis has been frequently reported as endocrinopathy (2) , whereas, an anti-cytotoxic T lymphocyte antigen4 (CTLA4) antibody, a similar immunomodulatory drug to nivolumab, was reported to induce hypophysitis leading to panhypopituitarism or multiple hormone deficiency (6) .
We here describe the first case reports of adrenal insufficiency caused by isolated adrenocorticotropic hormone (ACTH) syndrome without enlargement of the pituitary gland, which was probably induced by nivolumab. These two cases indicate that both CTLA4 and PD1 antibodies might induce disturbances of the pituitary gland, although the frequency is low. Nonetheless, adrenal insufficiency should not be misdiagnosed, thus allowing effective treatment with immune checkpoint inhibitors.
Case report

Case 1
A 39-year-old man was admitted with complaints of fatigue and dizziness. In 2008, he was diagnosed with malignant ocular melanoma and he underwent enucleation. In 2012, the patient developed metastases to the lungs, bones and liver. Chemotherapy was performed but did not improve disease progression; therefore, nivolumab, anti-PD1 antibody therapy, was started from October 2014. Intravenous administration of nivolumab (2 mg/kg) was repeated once every 3 weeks. A computed tomography scan at January 2015 revealed no progression of the metastatic tumors in the lungs, bones and liver. At the time of the 13th course of nivolumab therapy in July 2015, he complained of general malaise. His laboratory data showed a mild elevation of eosinophils (6.3%) and a white blood cell count of 6130 μl -1 , but sodium and glucose were normal. Serum examination revealed that basal ACTH and cortisol levels were lower than the normal limits. Replacement therapy with 10 mg/daily hydrocortisone was started. The basal levels of other hormones were within normal limits (Table 1) . Growth hormone, luteinizing hormone, follicle stimulating hormone and thyroid stimulating hormone (TSH) showed sufficient responses by stimulation test. In contrast, ACTH and cortisol showed little response to corticotropinreleasing hormone (CRH) loading (Fig. 1A) . A prolonged ACTH loading test showed the gradual elevation of serum and urine cortisol levels, excluding the primary adrenal insufficiency (Fig. 1B) . Magnetic resonance imaging (MRI) findings of the pituitary gland showed no abnormalities ( Fig. 2A and B) . Consequently, we diagnosed the patient with isolated ACTH deficiency as Grade 3 irAE, induced by nivolumab and continued hydrocortisone replacement up to 25 mg/day. His human leukocyte antigen (HLA) type was A11/A24, B60/B51, DR4/DR8 and DQB1, 040101/DQB1, 060101.
Case 2
A 50-year-old woman diagnosed with right sole malignant melanoma at the age of 45 years presented with heaviness of her head and appetite loss. She was diagnosed with multiple lung metastases of melanoma 1 year previously, and treated with chemotherapy unsuccessfully. Then, she was started on nivolumab from January 2015. After 13 courses of treatment, nivolumab was changed to ipilimumab from October 2015 because of lung metastatic melanoma progression. Just after the second administration of ipilimumab, she complained of fever, severe fatigue, dizziness and difficulty in standing. Her laboratory data showed elevation of eosinophils (11.5%) and a white blood cell count of 5280 μl -1 , but sodium and glucose were normal. Plasma ACTH and cortisol levels were lower than the assay sensitivity threshold (Table 1) . MRI findings showed no abnormalities as for Case 1 (Fig. 2C and D) . Her HLA type was A2/A26, B7/B62, Cw9/Cw7 and DR1/DR15.
Her general condition had rapidly improved after the intravenous administration of hydrocortisone 200 mg/day and thereafter hydrocortisone replacement (15 mg/day) was continued. Although ACTH and cortisol levels showed no response to CRH loading at any point, other anterior pituitary hormones showed sufficient responses for each stimulation test (Fig. 1C) . Despite poor serum cortisol responses to ACTH loading, serum and urine cortisol levels showed sufficient responses for prolonged ACTH loading (Fig. 1D) . Consequently, she was diagnosed with isolated ACTH syndrome as Grade 4 irAE.
Discussion
Here, we describe the first two case reports of secondary adrenal insufficiency. These cases were isolated ACTH deficiency probably induced by an autoimmune-related mechanism caused by nivolumab. Although one case of hypophysitis related to nivolumab was previously reported in a clinical study (2) , there has been no 'detailed' clinical report. In contrast to conventional hypophysitis, the MRI findings in our two cases showed no enlargement of the pituitary gland (7) .
Endocrinological examination revealed that the two cases were isolated ACTH deficiency. Other pituitary functions were preserved and the elevated TSH levels of Case 1 returned to normal after hydrocortisone replacement, although we could not exclude thyroiditis. The blunted cortisol response to temporal ACTH loading and the low dehydroepiandrosterone-sulfate level suggested the long-term suppression of ACTH in both cases (8, 9) . Therefore, we assumed that nivolumab was also the causative drug in Case 2; however, ipilimumab therapy was reported to cause hypopituitarism with a relatively high incidence (up to 8%), with the median time interval between the first treatment and presentation of about 9-16 weeks (1,10). In this context, because our patients were treated with 13-time courses of nivolumab without metastasis to the pituitary gland, nivolumabinduced isolated ACTH deficiency might have taken longer to present compared with other irAEs.
In cases of hypophysitis, enlargement of the pituitary gland (up to 60-100% of baseline size), with thickening of the stalk can be seen by MRI (11) . A radiological follow-up study reported that 181 cases (88%) of 204 autoimmune hypophysitis patients showed initial swelling of the pituitary gland (12) . Anti-CTLA4 antibodyinduced hypophysitis was also reported to show an enlarged pituitary gland in all cases (10) . Our cases suggested that nivolumab caused isolated ACTH deficiency without pituitary gland enlargement. This alerted us to a clinically important message that we should not misdiagnose treatable irAEs based on the decoy of normal MRI presentation of pituitary imaging.
Nivolumab-induced pituitary disturbances may allow us to resolve the autoimmune mechanism of isolated ACTH syndrome. Isolated ACTH deficiency is increasingly recognized as an autoimmune disease, but its detailed pathogenic mechanisms have not been reported (13) . Lymphocytic infiltration in the anterior lobe was demonstrated by pathological examination in some definitively diagnosed cases (14) . Histological analyses of tissues involved in irAEs caused by anti-PD1 antibody indicated the presence of CD8+ T lymphocyte or CD68+ macrophage infiltration and a reduction of forkhead box P3+ regulatory T cells in the heart (15) and an infiltration of lymphocytes in the skin (16) . Furthermore, PD1 deficient mice (17) were reported to develop tissue-specific autoimmune conditions. Although T lymphocyte-mediated corticotroph destruction might occur, further investigations are required to clarify the mechanism involved in isolated ACTH deficiency induced by nivolumab. 18 F-FDG PET-CT might provide more information regarding the presence of hypophysitis (18) . Furthermore, ipilimumab might have affected the isolated ACTH syndrome evoked by nivolumab. HLA typing revealed that Case 1 was A24 and DR4, and Case 2 was A2, B7 and DR1. These HLA types have been reported to be associated with lymphocytic hypophysitis (19, 20) , suggesting HLA may play a role in the different immune responses caused by nivolumab and anti-CTLA4 antibody (21) .
Conclusion
We report two cases of adrenal insufficiency probably induced by nivolumab. These cases provide two important messages. First, nivolumab may have induced the autoimmune-related isolated ACTH syndrome. Second, the affected pituitary glands showed no enlargement in contrast to most autoimmune hypophysitis cases typically determined by MRI. Therefore, MRI of the head might be ineffective to confirm the diagnosis of secondary adrenal insufficiency induced by nivolumab. Attention to hidden irAEs behind the patients' symptoms may be required for the successful treatment of patients with immune checkpoint inhibitors.
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